Subscribe to Biological Therapies in Psychiatry -  Choose your plan >
IN THIS MONTH'S ISSUE:
October 2017

PANDAS
In a large, population-based cohort study, streptococcal infections were associated with an increased risk of childhood obsessive-compulsive disorder (OCD) and tic disorders.

Mortality in Schizophrenia: Do Antipsychotics Increase the Risk?
Treatment with antipsychotics appears to decrease the long-term risk of mortality in adults with schizophrenia.

Suvorexant (Belsomra) to Prevent Delirium?
Compared with placebo, suvorexant (Belsomra) decreased the risk of delirium in one study of elderly hospitalized patients.

Lithium Risks in Pregnancy
Lithium use during the first trimester of pregnancy can raise the chances of cardiac malformations in babies, but the risk is much lower than previously believed.

In Brief
Oxytocin May Help Treat Negative Symptoms of Schizophrenia but Seems to Have No Effect on Social Cognitive Function; Rates of Suicide among US Teens Have Increased Dramatically Since 2007

Bipolar Depression: Ongoing Search for New Avenues
Adjunctive dopamine-enhancing agents may merit a role in treatment algorithms for bipolar depression, but no benefit was found for the glutamatergic modulator riluzole (Rilutek).

A Message from Alan J. Gelenberg, M.D.

When I first started writing BTP in the 1970s, it was to bridge the gap between new knowledge in our field and its application to patient care. Over the decades since, the need for this bridge has become even greater. Neuroscience rockets forward. Psychiatrists and other clinicians have a broader array of treatments for patients with mental disorders than we even dreamed of back then. But we have less time to spend with patients and less time to keep up with developments that affect treatment decisions. Our medications, and those prescribed by colleagues in other specialties, are more varied, complex, and prone to interactions. What were formerly crisp boundaries between major psychopharmacologic categories are now murky.

This makes the modern practice of psychiatry challenging—but also fun and promising. With the expanding armamentarium of treatment options comes enhanced ability to alleviate suffering. The mission of BTP remains constant, even while the field grows. We are still here to bridge the gap, to make science applicable and relevant, and to help you in your day-to-day work relieve distress and improve function in patients' lives.